D. L. Hershman, C. Lacchetti, R. H. Dworkin, E. M. Lavoie-smith, J. Bleeker et al., Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.32, issue.18, pp.1941-1967, 2014.

?. , Current guidelines in the management of ureteric calculi, 2016.

P. Perucca and F. G. Gilliam, Adverse effects of antiepileptic drugs, The Lancet Neurology, vol.11, issue.9, pp.792-802, 2012.

M. Mevaag, O. Henning, A. Baftiu, A. G. Granas, S. I. Johannessen et al., Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs, Acta Neurologica Scandinavica, vol.135, issue.1, pp.80-87, 2016.

F. G. Gilliam, A. J. Fessler, G. Baker, V. Vahle, J. Carter et al., Systematic screening allows reduction of adverse antiepileptic drug effects: A randomized trial, Neurology, vol.62, issue.1, pp.23-27, 2004.

E. P. Calandre, F. Rico-villademoros, and M. Slim, Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use, Expert Review of Neurotherapeutics, vol.16, issue.11, pp.1263-1277, 2016.

C. P. Panayiotopoulos, Gabapentin, Antiepileptic Drugs, Pharmacopoeia, pp.27-29, 2010.

C. S. Landefeld and M. A. Steinman, The Neurontin Legacy ? Marketing through Misinformation and Manipulation, New England Journal of Medicine, vol.360, issue.2, pp.103-106, 2009.

G. J. Sills, The mechanisms of action of gabapentin and pregabalin, Current Opinion in Pharmacology, vol.6, issue.1, pp.108-113, 2006.

, Works Cited, Globalization and Human Rights, pp.257-300, 2019.

N. Attal, G. Cruccu, R. Baron, M. Haanpää, P. Hansson et al., EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision, European Journal of Neurology, vol.17, issue.9, pp.1113-e88, 2010.

P. J. Wiffen, S. Derry, and R. F. Bell, Gabapentin for chronic neuropathic pain in adults, Cochrane Database Syst Rev, vol.6, p.7938, 2017.

T. L. Mersfelder and W. H. Nichols, Gabapentin, Annals of Pharmacotherapy, vol.50, issue.3, pp.229-233, 2015.

R. V. Smith, J. R. Havens, and S. L. Walsh, Gabapentin misuse, abuse and diversion: a systematic review, Addiction, vol.111, issue.7, pp.1160-1174, 2016.

K. E. Evoy, J. R. Covvey, A. M. Peckham, L. Ochs, and K. E. Hultgren, Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS), Research in Social and Administrative Pharmacy, vol.15, issue.8, pp.953-958, 2019.

J. E. Frampton, Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder, CNS Drugs, vol.28, issue.9, pp.835-854, 2014.

I. H. Iftikhar, L. Alghothani, and L. M. Trotti, Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis, European Journal of Neurology, vol.24, issue.12, pp.1446-1456, 2017.

D. K. Baidya, A. Agarwal, and P. Khanna, Pregabalin in acute and chronic pain, J Anaesthesiol Clin Pharmacol, vol.27, pp.307-314, 2011.

J. S. Bryans and D. J. Wustrow, 3-Substituted GABA analogs with central nervous system activity: A review, Medicinal Research Reviews, vol.19, issue.2, pp.149-177, 1999.

B. A. Lauria-horner and R. B. Pohl, Pregabalin: a new anxiolytic, Expert Opinion on Investigational Drugs, vol.12, issue.4, pp.663-672, 2003.

O. Enke, H. A. New, C. H. New, S. Mathieson, A. J. Mclachlan et al., Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis, Canadian Medical Association Journal, vol.190, issue.26, pp.E786-E793, 2018.

H. Shanthanna, I. Gilron, M. Rajarathinam, R. Alamri, S. Kamath et al., Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials, PLOS Medicine, vol.14, issue.8, p.e1002369, 2017.

M. I. Bennett, B. Laird, C. Van-litsenburg, and M. Nimour, Pregabalin for the Management of Neuropathic Pain in Adults with Cancer: A Systematic Review of the Literature, Pain Medicine, vol.14, issue.11, pp.1681-1688, 2013.

M. Linde, W. M. Mulleners, E. P. Chronicle, and D. C. Mccrory, Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults, Cochrane Database of Systematic Reviews, 2013.

H. Clarke, R. P. Bonin, B. A. Orser, M. Englesakis, D. N. Wijeysundera et al., The Prevention of Chronic Postsurgical Pain Using Gabapentin and Pregabalin, Anesthesia & Analgesia, vol.115, issue.2, pp.428-442, 2012.

L. E. Chaparro, S. A. Smith, R. A. Moore, P. J. Wiffen, and I. Gilron, Pharmacotherapy for the prevention of chronic pain after surgery in adults, Cochrane Database of Systematic Reviews, p.8307, 2013.

S. Derry, R. F. Bell, S. Straube, P. J. Wiffen, D. Aldington et al., Pregabalin for neuropathic pain in adults, Cochrane Database of Systematic Reviews, vol.1, p.7076, 2019.

D. M. Simpson, A. S. Rice, B. Emir, J. Landen, D. Semel et al., A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy, Pain, vol.155, issue.10, pp.1943-1954, 2014.

L. M. Arnold, S. Whitaker, C. Hsu, D. Jacobs, and D. Merante, Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study, Current Medical Research and Opinion, vol.35, issue.10, pp.1825-1835, 2019.

D. Merante, J. Rosenstock, U. Sharma, K. Feins, C. Hsu et al., Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study, Pain Medicine, vol.18, pp.2198-2207, 2017.

J. Mendell, N. Levy-cooperman, E. Sellers, B. Vince, D. Kelsh et al., Abuse potential of mirogabalin in recreational polydrug users, Therapeutic Advances in Drug Safety, vol.10, p.204209861983603, 2019.

H. Cheung, D. Kamp, and E. Harris, An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels, Epilepsy Res, vol.13, pp.107-112, 1992.

M. Dibué-adjei, M. A. Kamp, S. Alpdogan, E. E. Tevoufouet, W. F. Neiss et al., Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo, Cellular Physiology and Biochemistry, vol.44, issue.3, pp.935-947, 2017.

M. Silver, D. Blum, J. Grainger, A. E. Hammer, and S. Quessy, Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain, Journal of Pain and Symptom Management, vol.34, issue.4, pp.446-454, 2007.

D. Choi, J. P. Stables, and H. Kohn, Synthesis and Anticonvulsant Activities ofN-Benzyl-2-acetamidopropionamide Derivatives, Journal of Medicinal Chemistry, vol.39, issue.9, pp.1907-1916, 1996.

. Abou-khalil and . Bw, Update on Antiepileptic Drugs 2019, CONTINUUM: Lifelong Learning in Neurology, vol.25, issue.2, pp.508-536, 2019.

C. Zona, I. Niespodziany, C. Marchetti, H. Klitgaard, G. Bernardi et al., Levetiracetam does not modulate neuronal voltage-gated Na+and T-type Ca2+currents, Seizure, vol.10, issue.4, pp.279-286, 2001.

E. A. Lukyanetz, V. M. Shkryl, and P. G. Kostyuk, Selective Blockade of N-Type Calcium Channels by Levetiracetam, Epilepsia, vol.43, issue.1, pp.9-18, 2002.

B. A. Lynch, N. Lambeng, K. Nocka, P. Kensel-hammes, S. M. Bajjalieh et al., The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, Proceedings of the National Academy of Sciences, vol.101, issue.26, pp.9861-9866, 2004.

J. V. Holbech, M. Otto, F. W. Bach, T. S. Jensen, and S. H. Sindrup, 489 THE ANTICONVULSANT LEVETIRACETAM FOR THE TREATMENT OF PAIN IN POLYNEUROPATHY. A RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER TRIAL, European Journal of Pain Supplements, vol.4, issue.S1, pp.138-138, 2010.

O. J. Vilholm, S. Cold, L. Rasmussen, and S. H. Sindrup, Effect of levetiracetam on the postmastectomy pain syndrome, European Journal of Neurology, vol.15, issue.8, pp.851-857, 2008.

E. Mesdjian, L. Ciesielski, M. Valli, B. Bruguerolle, G. Jadot et al., Sodium valproate: Kinetic profile and effects on GABA levels in various brain areas of the rat, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.6, issue.3, pp.223-233, 1982.

P. Gean, C. Huang, C. Hung, and J. Tsai, Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices, Brain Research Bulletin, vol.33, issue.3, pp.333-336, 1994.

A. M. Vandongen, M. G. Vanerp, and R. A. Voskuyl, Valproate Reduces Excitability by Blockage of Sodium and Potassium Conductance, Epilepsia, vol.27, issue.3, pp.177-182, 1986.

E. Perucca, Pharmacological and Therapeutic Properties of Valproate, CNS Drugs, vol.16, issue.10, pp.695-714, 2002.

H. Meunier, G. Carraz, and Y. Neunier,

P. C. Warner, Discussion: ?Half Sommerfeld Approximation for Finite Journal Bearings? (Fedor, J. V., 1963, ASME J. Basic Eng., 85, pp. 435?438), Journal of Basic Engineering, vol.85, issue.3, pp.438-438, 1963.

R. P. Agrawal, J. Goswami, S. Jain, and D. K. Kochar, Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study, Diabetes Research and Clinical Practice, vol.83, issue.3, pp.371-378, 2009.

N. D. Grover, R. P. Limaye, T. R. Patil, and D. V. Gokhale, Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson?s disease, Indian Journal of Pharmacology, vol.45, issue.6, p.547, 2013.

C. L. Schauf, Zonisamide enhances slow sodium inactivation inMyxicola, Brain Research, vol.413, issue.1, pp.185-188, 1987.

E. Bourinet, A. Francois, and S. Laffray, T-type calcium channels in neuropathic pain, PAIN, vol.157, issue.1, pp.S15-S22, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01942457

B. Hanrahan, R. P. Carson, . Ethosuximide, and . Statpearls, Works Cited, Hidden Treasure, pp.19-22, 2019.

A. Van-wieringen and C. M. Vrijlandt, Ethosuximide intoxication caused by interaction with isoniazid, Neurology, vol.33, issue.9, pp.1227-1227, 1983.

W. Kuhnz, S. Koch, S. Jakob, A. Hartmann, H. Helge et al., Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status., British Journal of Clinical Pharmacology, vol.18, issue.5, pp.671-677, 1984.

E. Faught, G. L. Holmes, W. E. Rosenfeld, G. Novak, W. Neto et al., Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures, Neurology, vol.71, issue.20, pp.1586-1593, 2008.

Y. Liu, G. J. Yohrling, Y. Wang, T. L. Hutchinson, D. E. Brenneman et al., Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons, Epilepsy Research, vol.83, issue.1, pp.66-72, 2009.

C. Lee, M. Lee, C. Shih, and H. Liou, Carisbamate (RWJ-333369) inhibits glutamate transmission in the granule cell of the dentate gyrus, Neuropharmacology, vol.61, issue.8, pp.1239-1247, 2011.

S. Shim, M. El-mansari, and P. Blier, Modulation of the Antidepressant-Like Effects of Sustained Administration of Carisbamate and Lamotrigine on Monoaminergic Systems: Electrophysiological Studies in the Rat Brain, Journal of Pharmacology and Experimental Therapeutics, vol.347, issue.2, pp.487-496, 2013.

D. Y. Kim, F. Zhang, S. T. Nakanishi, T. Mettler, I. Cho et al., Carisbamate blockade of T-type voltage-gated calcium channels, Epilepsia, vol.58, issue.4, pp.617-626, 2017.

J. J. Halford, E. Ben-menachem, P. Kwan, S. Ness, J. Schmitt et al., A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures, Epilepsia, vol.52, issue.4, pp.816-825, 2011.

M. R. Sperling, A. Greenspan, J. A. Cramer, P. Kwan, R. Kälviäinen et al., Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials, Epilepsia, vol.51, issue.3, pp.333-343, 2010.

K. Kulig and B. Malawska, Carisbamate, a new carbamate for the treatment of epilepsy, IDrugs, vol.10, pp.720-727, 2007.

S. J. Nolan, M. Muller, C. Tudur-smith, and A. G. Marson, Oxcarbazepine versus phenytoin monotherapy for epilepsy, Cochrane Database of Systematic Reviews, vol.003615, 2013.

M. W. Koch and S. K. Polman, Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures, Cochrane Database of Systematic Reviews, vol.006453, 2009.

M. J. Mclean, M. Schmutz, A. W. Wamil, H. Olpe, C. Portet et al., Oxcarbazepine: Mechanisms of Action, Epilepsia, vol.35, issue.s3, pp.S5-S9, 1994.

A. Stefani, A. Pisani, M. Murtas, N. B. Mercuri, M. G. Marciani et al., Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High-Voltage-Activated Calcium Currents, Epilepsia, vol.36, issue.10, pp.997-1002, 1995.

P. J. Wiffen, S. Derry, R. A. Moore, and E. A. Kalso, Carbamazepine for chronic neuropathic pain and fibromyalgia in adults, Cochrane Database of Systematic Reviews, p.5451, 2014.

H. Harke, P. Gretenkort, H. U. Ladleif, S. Rahman, and O. Harke, The Response of Neuropathic Pain and Pain in Complex Regional Pain Syndrome I to Carbamazepine and Sustained-Release Morphine in Patients Pretreated with Spinal Cord Stimulation: A Double-Blinded Randomized Study, Anesthesia and Analgesia, vol.92, issue.2, pp.488-495, 2001.

S. Dogra, S. Beydoun, J. Mazzola, M. Hopwood, and Y. Wan, Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study, European Journal of Pain, vol.9, issue.5, pp.543-543, 2005.

D. T. Demant, K. Lund, J. Vollert, C. Maier, M. Segerdahl et al., The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study, Pain, vol.155, issue.11, pp.2263-2273, 2014.

N. B. Finnerup, S. Haroutounian, R. Baron, R. H. Dworkin, I. Gilron et al., Neuropathic pain clinical trials, PAIN, vol.159, issue.11, pp.2339-2346, 2018.

F. P. Bymaster, E. E. Beedle, J. Findlay, P. T. Gallagher, J. H. Krushinski et al., Duloxetine (Cymbalta?), a dual inhibitor of serotonin and norepinephrine reuptake, Bioorganic & Medicinal Chemistry Letters, vol.13, issue.24, pp.4477-4480, 2003.

F. P. Bymaster, T. C. Lee, M. P. Knadler, M. Detke, and S. Iyengar, The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression, Current Pharmaceutical Design, vol.11, issue.12, pp.1475-1493, 2005.

S. Wang, J. Calderon, and G. Kuo-wang, Block of Neuronal Na+Channels by Antidepressant Duloxetine in a State-dependent Manner, Anesthesiology, vol.113, issue.3, pp.655-665, 2010.

D. Food and . Administration, Safety-Related Drug Labeling Changes Approved by FDA, 1997.

E. A. Muth, J. T. Haskins, J. A. Moyer, G. E. Husbands, S. T. Nielsen et al., Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative, Biochemical Pharmacology, vol.35, issue.24, pp.4493-4497, 1986.

B. A. Rappaport, NDA 22-256 Savella Addendum to Division Director Review and Summary Basis for Approval Recommendation [Internet]. Food and Drug Administration, 2009.

P. Fangmann, H. Assion, G. Juckel, C. Á. González, and F. López-muñoz, Half a Century of Antidepressant Drugs, Journal of Clinical Psychopharmacology, vol.28, issue.1, pp.1-4, 2008.

M. Tatsumi, K. Groshan, R. D. Blakely, and E. Richelson, Pharmacological profile of antidepressants and related compounds at human monoamine transporters, European Journal of Pharmacology, vol.340, issue.2-3, pp.249-258, 1997.

M. J. Owens, W. N. Morgan, and S. J. Plott, Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites, J. Pharmacol. Exp. Ther, vol.283, pp.1305-1322, 1997.

L. Rauser, J. E. Savage, and H. Y. Meltzer, Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor, J. Pharmacol. Exp. Ther, vol.299, pp.83-89, 2001.

M. A. Sills and P. S. Loo, Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate, Mol. Pharmacol, vol.36, pp.160-165, 1989.

J. J. Pancrazio, G. L. Kamatchi, and A. K. Roscoe, Inhibition of neuronal Na+ channels by antidepressant drugs, J. Pharmacol. Exp. Ther, vol.284, pp.208-214, 1998.

M. A. Punke and P. Friederich, Amitriptyline Is a Potent Blocker of Human Kv1.1 and Kv7.2/7.3 Channels, Anesthesia & Analgesia, vol.104, issue.5, pp.1256-1264, 2007.

S. Jang, X. Liu, C. Chan, D. Weinshenker, R. A. Hall et al., Amitriptyline is a TrkA and TrkB Receptor Agonist that Promotes TrkA/TrkB Heterodimerization and Has Potent Neurotrophic Activity, Chemistry & Biology, vol.16, issue.6, pp.644-656, 2009.

D. Pastoor and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression, Expert Opinion on Drug Metabolism & Toxicology, vol.10, issue.1, pp.121-128, 2013.

A. Van-gastel, Drug-Induced Insomnia and Excessive Sleepiness, Sleep Medicine Clinics, vol.13, issue.2, pp.147-159, 2018.

O. A. Shoair, A. N. Nyandege, and P. W. Slattum, Medication-Related Dizziness in the Older Adult, Otolaryngologic Clinics of North America, vol.44, issue.2, pp.455-471, 2011.

A. O. Oladapo, J. C. Barner, K. L. Rascati, and S. A. Strassels, A Retrospective Database Analysis of Neuropathic Pain and Oral Antidiabetic Medication Use and Adherence Among Texas Adults With Type 2 Diabetes Enrolled in Medicaid, Clinical Therapeutics, vol.34, issue.3, pp.605-613, 2012.

L. Timmerman, D. L. Stronks, J. G. Groeneweg, and F. J. Huygen, Prevalence and determinants of medication non-adherence in chronic pain patients: a systematic review, Acta Anaesthesiologica Scandinavica, vol.60, issue.4, pp.416-431, 2016.

P. Butow and L. Sharpe, The impact of communication on adherence in pain management, Pain, vol.154, issue.1, pp.S101-S107, 2013.

S. Singh and Y. K. Loke, Drug safety assessment in clinical trials: methodological challenges and opportunities, Trials, vol.13, issue.1, p.138, 2012.

G. Prada-ramallal, B. Takkouche, and A. Figueiras, Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches, Drug Safety, vol.40, issue.7, pp.547-558, 2017.

K. F. Schulz, D. G. Altman, and D. Moher, CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials, BMJ, vol.340, issue.mar23 1, pp.c332-c332, 2010.

?. , Current guidelines for double-blind, placebo-controlled

D. G. Perahia, D. K. Kajdasz, D. J. Walker, J. Raskin, and A. Tylee, Duloxetine 60 mg once daily in the treatment of milder major depressive disorder, International Journal of Clinical Practice, vol.60, issue.5, pp.613-620, 2006.

D. G. Perahia, D. K. Kajdasz, D. J. Walker, J. Raskin, and A. Tylee, Duloxetine 60 mg once daily in the treatment of milder major depressive disorder, International Journal of Clinical Practice, vol.60, issue.5, pp.613-620, 2006.

. Ziegler, The ?Assigned Residence? Case: H.C. 7015, 7019/02 Kipah Ajuri et al. v. IDF Commander in The West Bank et al., Israel Law Review, vol.36, issue.1, pp.179-195, 2002.

D. G. Perahia, D. K. Kajdasz, D. J. Walker, J. Raskin, and A. Tylee, Duloxetine 60 mg once daily in the treatment of milder major depressive disorder, International Journal of Clinical Practice, vol.60, issue.5, pp.613-620, 2006.

M. Wohlreich, P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, p.S242, 2003.

. Goldstein,

J. Raskin, J. Y. Xu, and D. K. Kajdasz, Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder, International Psychogeriatrics, vol.20, issue.02, 2007.

M. Wohlreich, P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, issue.8, p.S242, 2003.

J. V. Pergolizzi, R. B. Raffa, R. Taylor, G. Rodriguez, S. Nalamachu et al., A Review of Duloxetine 60 mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain, Pain Practice, vol.13, issue.3, pp.239-252, 2012.

S. Brecht, D. Desaiah, E. Marechal, A. Santini, J. Podhorna et al., P.1.c.012 Efficacy and safety of duloxetine 60-mg and 120-mg daily in patients hospitalised for severe depression, European Neuropsychopharmacology, vol.19, issue.5, p.S258, 2009.

. Dizziness, Lidocaine/magnesium, Reactions Weekly, vol.1508, issue.1, pp.23-23, 2014.

M. Wohlreich, P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, p.S242, 2003.

M. Wohlreich, P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, issue.1, p.S242, 2003.